Atossa Therapeutics, Inc.’s Post

🧬 In a retrospective analysis, Arnab Basu, M.D., MPH, Assistant Professor in the UAB Division of Hematology and Oncology, found that patients with muscle-invasive bladder cancer who had detectable circulating tumor DNA before radical cystectomy had shorter disease-free survival and higher recurrence rates. Learn More ➡️ https://lnkd.in/ekK6BK3N

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promising safety and response results among patients with locally advanced mismatch repair-deficient colon cancer. Learn more: https://lnkd.in/ec2bZMTN

A very nice overview of the current staples and the new advances in the area of ADCs for breast cancer. Very helpful for increasing comprehension of various BC treatment strategies. Educational note to self: it was interesting to revise that the bystander effect of ADCs plays such a major role in their mechanism of action and that some therapeutic mAbs are specifically engineered to increase this effect, for instance via the intricate designs of the linker fragments or by selection of more membrane-permeable payloads. T-DXd is a fabulous example of such design, a mAb with high drug-antibody ratio and a cleavable linker, proving effective not only in HER2 3+ BC, but also in HER2-low BC by targeting heterogenous tumor cells in addition to the antigen-positive targets. Noting this sent me reading more about ADC design, here are a couple of sources that proved very informative: https://lnkd.in/eeZxrycs https://lnkd.in/eCT9z54h

Ahead of SABCS, We asked Dr. rena callahan, an expert in breast cancer, about the latest advancements in #breastcancer research within the last year. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need; from the experts you want to hear from. #OnvivExpertNetwork #Pharma #BreastCancerResearch #SABCS

📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

HER2 has evolved into a tumor-agnostic biomarker. By identifying HER2-positive tumors across multiple cancer types, we can expand the use of targeted therapies like antibody-drug conjugates (ADCs), ultimately improving outcomes for patients with cancer. Learn more: https://lnkd.in/eZUkf2h6

HER2 has evolved into a tumor-agnostic biomarker. By identifying HER2-positive tumors across multiple cancer types, we can expand the use of targeted therapies like antibody-drug conjugates (ADCs), ultimately improving outcomes for patients with cancer. Learn more: https://lnkd.in/ei-3U6-e

Very interesting comment and perspective on the I-SPY platform (https://lnkd.in/eaJSUmav). I-SPY 'clinical trials are creating a roadmap for a new clinical research vision that cuts inefficiencies, puts patients first, and defines a viable pathway for precision-based drug development. The question now is whether others will replicate the approach outside of breast cancer.' Interesting approach with a variety of applications. See Biocentury article: https://lnkd.in/em4SipbT

HER2 has evolved into a tumor-agnostic biomarker. By identifying HER2-positive tumors across multiple cancer types, we can expand the use of targeted therapies like antibody-drug conjugates (ADCs), ultimately improving outcomes for patients with cancer. Learn more: https://lnkd.in/e9wg9Dk6

I am thrilled to share our recent publication entitled "Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay" in Medical Oncology Journal, Q2 Thanks for the whole team https://lnkd.in/dYRBB_zF